CDK4 is altered in 2.46% of malignant solid tumor patients with CDK4 Mutation present in 0.46% of all malignant solid tumor patients [4].

CDK4 Mutation is an inclusion criterion in 6 clinical trials for malignant solid tumor, of which 5 are open and 1 is closed. Of the trials that contain CDK4 Mutation and malignant solid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 5 are phase 2 (4 open) [5].

CDK4 is altered in 1.21% of breast carcinoma patients with CDK4 Mutation present in 0.22% of all breast carcinoma patients [4].

CDK4 Mutation is an inclusion criterion in 2 clinical trials for breast carcinoma, of which 0 are open and 2 are closed. Of the trials that contain CDK4 Mutation and breast carcinoma as inclusion criteria, 2 are phase 2 (0 open) [5].

CDK4 is altered in 0.4% of non-hodgkin lymphoma patients with CDK4 Mutation present in 0.13% of all non-hodgkin lymphoma patients [4].

CDK4 Mutation is an inclusion criterion in 2 clinical trials for non-hodgkin lymphoma, of which 2 are open and 0 are closed. Of the trials that contain CDK4 Mutation and non-hodgkin lymphoma as inclusion criteria, 2 are phase 2 (2 open) [5].

CDK4 is altered in 1.99% of endometrial endometrioid adenocarcinoma patients with CDK4 Mutation present in 1.91% of all endometrial endometrioid adenocarcinoma patients [4].

CDK4 Mutation is an inclusion criterion in 1 clinical trial for endometrial endometrioid adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 Mutation and endometrial endometrioid adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDK4 is altered in 3.68% of melanoma patients with CDK4 Mutation present in 1.41% of all melanoma patients [4].

CDK4 Mutation is an inclusion criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 Mutation and melanoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDK4 is altered in 1.6% of squamous cell lung carcinoma patients with CDK4 Mutation present in 0.74% of all squamous cell lung carcinoma patients [4].

CDK4 Mutation is an inclusion criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 Mutation and squamous cell lung carcinoma as inclusion criteria, 1 is no phase specified (1 open) [5].

CDK4 is altered in 0.75% of head and neck squamous cell carcinoma patients with CDK4 Mutation present in 0.66% of all head and neck squamous cell carcinoma patients [4].

CDK4 Mutation is an inclusion criterion in 1 clinical trial for head and neck squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 Mutation and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDK4 is altered in 0.71% of colorectal carcinoma patients with CDK4 Mutation present in 0.58% of all colorectal carcinoma patients [4].

CDK4 Mutation is an inclusion criterion in 1 clinical trial for colorectal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CDK4 Mutation and colorectal carcinoma as inclusion criteria, 1 is phase 2 (0 open) [5].

CDK4 is altered in 0.48% of multiple myeloma patients with CDK4 Mutation present in 0.48% of all multiple myeloma patients [4].

CDK4 Mutation is an inclusion criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 Mutation and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDK4 is altered in 2.3% of cancer patients with CDK4 Mutation present in 0.43% of all cancer patients [4].

CDK4 Mutation is an inclusion criterion in 1 clinical trial for cancer, of which 0 are open and 1 is closed. Of the trial that contains CDK4 Mutation and cancer as inclusion criteria, 1 is phase 2 (0 open) [5].

CDK4 is altered in 1.17% of esophageal carcinoma patients with CDK4 Mutation present in 0.35% of all esophageal carcinoma patients [4].

CDK4 Mutation is an inclusion criterion in 1 clinical trial for esophageal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CDK4 Mutation and esophageal carcinoma as inclusion criteria, 1 is phase 2 (0 open) [5].

CDK4 is altered in 1.4% of gastric carcinoma patients with CDK4 Mutation present in 0.25% of all gastric carcinoma patients [4].

CDK4 Mutation is an inclusion criterion in 1 clinical trial for gastric carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CDK4 Mutation and gastric carcinoma as inclusion criteria, 1 is phase 2 (0 open) [5].

CDK4 is altered in 0.52% of ovarian carcinoma patients with CDK4 Mutation present in 0.22% of all ovarian carcinoma patients [4].

CDK4 Mutation is an inclusion criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 Mutation and ovarian carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDK4 is altered in 0.52% of ovarian epithelial tumor patients with CDK4 Mutation present in 0.22% of all ovarian epithelial tumor patients [4].

CDK4 Mutation is an inclusion criterion in 1 clinical trial for ovarian epithelial tumor, of which 1 is open and 0 are closed. Of the trial that contains CDK4 Mutation and ovarian epithelial tumor as inclusion criteria, 1 is phase 2 (1 open) [5].

CDK4 is altered in 0.52% of B-cell non-hodgkin lymphoma patients with CDK4 Mutation present in 0.17% of all B-cell non-hodgkin lymphoma patients [4].

CDK4 Mutation is an inclusion criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 Mutation and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDK4 is altered in 1.89% of fallopian tube carcinoma patients [4].

CDK4 Mutation is an inclusion criterion in 1 clinical trial for fallopian tube carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 Mutation and fallopian tube carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDK4 is altered in 0.54% of germ cell tumor patients [4].

CDK4 Mutation is an inclusion criterion in 1 clinical trial for germ cell tumor, of which 0 are open and 1 is closed. Of the trial that contains CDK4 Mutation and germ cell tumor as inclusion criteria, 1 is phase 2 (0 open) [5].

CDK4 is altered in 0.4% of histiocytic and dendritic cell neoplasm patients [4].

CDK4 Mutation is an inclusion criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains CDK4 Mutation and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

CDK4 is altered in 7.69% of mucosal melanoma patients [4].

CDK4 Mutation is an inclusion criterion in 1 clinical trial for mucosal melanoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 Mutation and mucosal melanoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDK4 is altered in 4.55% of primary peritoneal carcinoma patients [4].

CDK4 Mutation is an inclusion criterion in 1 clinical trial for primary peritoneal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 Mutation and primary peritoneal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].